Studies have shown that adjuvant YPFG therapy can improve the overall clinical response rate, increase serum immunoglobulin IgA, IgM, and IgG levels, and significantly decrease TNF-α levels, thereby reducing the rate of infection recurrence and improving children's immunity. This evidence concerns the gene CD79A and infection.